| Literature DB >> 29619786 |
Mohamed F Mostafa1, Ragaa Herdan1, Mohamed Elshazly2.
Abstract
BACKGROUND: Cleft lip and palate are common major congenital anomalies. Cleft palate (CP) repair causes pain and needs large doses of intravenous opioids. The risk of postoperative airway obstruction or respiratory depression is high, requiring continuous and vigilant monitoring. The primary outcome was to evaluate the efficacy of using different local anesthetics during bilateral maxillary nerve block (MNB) with general anesthesia on quality of recovery after primary CP repair. We hypothesized that levobupivacaine would be better than bupivacaine. Also, to investigate the potency of bilateral MNB in improving quality of postoperative analgesia.Entities:
Keywords: Bupivacaine; Cleft palate; Levobupivacaine; Maxillary nerve.
Year: 2018 PMID: 29619786 PMCID: PMC5903109 DOI: 10.4097/kjae.2018.71.2.135
Source DB: PubMed Journal: Korean J Anesthesiol ISSN: 2005-6419
Demographic Data of the Two Study Groups
| Variable | Group L (n = 30) | Group B (n = 30) | P value |
|---|---|---|---|
| Age (yr) | 3 (2) | 3 (2) | 0.701 |
| Sex | 0.422 | ||
| Male | 18 (60%) | 16 (53.3%) | |
| Female | 12 (40%) | 14 (46.7%) | |
| Weight (kg) | 14.1 (2.9) | 13.9 (3.2) | 0.219 |
| Height (cm) | 94.2 (12.0) | 97.2 (16.2) | 0.397 |
| Duration of surgery (min) | 79.5 (16.7) | 74.8 (19.1) | 0.233 |
Data are expressed as mean (SD) or number of patients (%). Group L: Levobupivacaine, Group B: Bupivacaine.
Postoperative Pain Scores of the Two Study Groups
| Variable | Group L (n = 30) | Group B (n = 30) | P value |
|---|---|---|---|
| FLACC score | |||
| 0 | 18 (60%) | 21 (70%) | 0.106 |
| 1 | 11 (36.7%) | 9 (30%) | |
| 2 | 1 (3.3%) | 0 (0%) | |
| Time of first analgesia (h) | 15.6 (1.9) | 16.0 (2.1) | 0.289 |
| Total amount of nalbuphine (mg) | 18.0 (2.7) | 17.1 (2.0) | 0.115 |
Data are expressed as mean (SD) or number of patients (%). Group L: Levobupivacaine, Group B: Bupivacaine. FLACC score: face, legs, activity, cry, and consolability score.
Length of Supplemental Analgesia Required in Both Study Groups
| Variable | Length of supplemental analgesia (h) | |||||||
|---|---|---|---|---|---|---|---|---|
| 0–10 | 12 | 14 | 16 | 18 | 20 | 22 | 24 | |
| Group L (n = 30) | 0 (0%) | 2 (6.7%) | 1 (3.3%) | 9 (30%) | 6 (20%) | 5 (16.7%) | 5 (16.7%) | 2 (6.7%) |
| Group B (n = 30) | 0 (0%) | 0 (0%) | 2 (6.7%) | 6 (20%) | 11 (36.7%) | 1 (3.3%) | 7 (23.3%) | 3 (10%) |
Data are expressed as number of patients (%). Group L: Levobupivacaine, Group B: Bupivacaine. Chi-square for trend = 3.458, df = 15, P = 0.041.
Sedation Scores of the Two Study Groups
| Sedation score | Group L (n = 30) | Group B (n = 30) | P value |
|---|---|---|---|
| 0 | 16 (53.3%) | 17 (56.7%) | 0.311 |
| 1 | 12 (40%) | 10 (33.3%) | |
| 2 | 2 (6.7%) | 3 (10%) |
Data are expressed as number of patients (%). Group L: Levobupivacaine, Group B: Bupivacaine.
Sevoflurane and Serum Glucose Levels in Both Study Groups
| Variable | Group L (n = 30) | Group B (n = 30) | P value |
|---|---|---|---|
| Sevoflurane (%) | 2–4% | 2–3% | 0.650 |
| Serum glucose (mg/dl) | |||
| Preoperative | 99.3 (27.2) | 101.9 (31.8) | 0.281 |
| After 15 min | 131.8 (34.1) | 130.6 (32.0) | 0.732 |
| After 2 h | 127.2 (41.7) | 128.0 (39.0) | 0.490 |
Data are expressed as mean (SD) or ranges. Group L: Levobupivacaine, Group B: Bupivacaine.